Fig. 2: Intravenous Synthetic RNA virus administration demonstrates viral replication in tumors and mediates tumor regression.
a–d Athymic nude mice implanted subcutaneously with NCI-H446 SCLC xenograft tumors. a, b Mice were treated via IV administration with either vehicle control (PBS), Synthetic-SVV-Neg, or Synthetic-SVV on Days 1, 8, and 15, at 1.0 mg/kg (n = 8 per group). a Tumor volume (mm3) and b body weight changes (%) were monitored. Tumor growth (mm3) and body weight changes (%) were monitored. Data are reported as mean ± s.e.m. Statistical significance was determined using a mixed linear model ***p < 0.001 vs. PBS and ^^^p < 0.001 vs. Synthetic-SVV-Neg. c, d Replication of Synthetic-SVV in NCI-H446 tumors after a single IV dose of 0.1 mg/kg SVV. c SVV negative-strand RNA levels were determined using RT-qPCR (n = 5 per time point). SVV infections particles (PFU) were determined by plaque assay. n = 3 independent tumor samples were assessed per timepoint. d FISH specific for SVV positive (red) and negative (white) RNA strands are shown for NCI-H466 tumor sections. Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI). These images are representative of four independent samples. Scale of the panel is indicated under the image. e, f Athymic nude mice (n = 7 per group) implanted subcutaneously with SK-MEL-28 human melanoma tumors were treated by IV administration with either vehicle control (PBS) or Synthetic-CVA21 on Days 1 and 8 at 2 different doses, 0.2 mg/kg or 0.05 mg/kg. e Tumor growth (mm3) and f body weight changes (%) were monitored. Data are reported as mean ± s.e.m. Statistical significance was determined using a mixed linear model ***p < 0.001 vs. PBS. Source data are provided as a Source Data file.
